Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) CEO Burke Thomas Barrett sold 50,000 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. The trade was a 44.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Pulse Biosciences Stock Performance
NASDAQ:PLSE traded up $0.19 during trading hours on Friday, hitting $17.98. The company's stock had a trading volume of 166,773 shares, compared to its average volume of 200,640. The stock has a fifty day simple moving average of $17.90 and a 200-day simple moving average of $16.57. Pulse Biosciences, Inc. has a twelve month low of $6.59 and a twelve month high of $22.69.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the company earned ($0.19) EPS.
Analysts Set New Price Targets
Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Thursday, December 12th.
Read Our Latest Analysis on Pulse Biosciences
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Quest Partners LLC bought a new stake in Pulse Biosciences during the 2nd quarter worth $91,000. Creative Planning boosted its stake in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after purchasing an additional 11,667 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Pulse Biosciences during the third quarter worth about $378,000. Rhumbline Advisers increased its stake in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after buying an additional 1,608 shares during the period. Finally, Barclays PLC raised its holdings in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after buying an additional 23,738 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
